TOP TEN perturbations for 1553514_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553514_a_at
Selected probe(set): 220528_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553514_a_at (220528_at) across 6672 perturbations tested by GENEVESTIGATOR:

psoriasis study 24 (lesional; baseline; etarnecept; non-responder) / psoriasis study 24 (non-lesional; baseline; etarnecept; non-responder)

Relative Expression (log2-ratio):5.194999
Number of Samples:13 / 13
Experimental psoriasis study 24 (lesional; baseline; etarnecept; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; etarnecept; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 20 (lesional) / psoriasis study 20 (non-lesional)

Relative Expression (log2-ratio):5.064313
Number of Samples:4 / 4
Experimental psoriasis study 20 (lesional)
Lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia preferentially near the central region of active plaques, except in cases where the center was poorly defined due to an irregular boundary. Regions near the edge of individual plaques were avoided to ensure that uninvolved skin was not included. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C.
Control psoriasis study 20 (non-lesional)
Non-lesional skin punch biopsies derived from patients with chronic plaque psoriasis. 6 mm punch biopsies were obtained under local anesthesia from the buttocks and at least 10 cm away from the nearest active psoriasis plaque. Patients with one or more psoriasis plaques not limited to the scalp area were enrolled to the study. In case that only one plaque was present, a patient was admitted when that plaque occupied more than 1% of the body surface area. Patients were advised not to apply topical treatments for at least 1 week prior to biopsies and not to use systemic medications for at least 2 weeks prior to sample biopsies. Biopsies were snap-frozen in liquid nitrogen, stored at -80°C.

psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.) / psoriasis study 5 (Zaba; lesional; etanercept; 1wk; resp.)

Relative Expression (log2-ratio):-5.021365
Number of Samples:6 / 11
Experimental psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis twelve weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:
Control psoriasis study 5 (Zaba; lesional; etanercept; 1wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis one week after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:

psoriasis study 25 (lesional; baseline; ustekinumab; non-responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)

Relative Expression (log2-ratio):4.966754
Number of Samples:10 / 9
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)

Relative Expression (log2-ratio):4.9354305
Number of Samples:10 / 9
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; baseline; ustekinumab; responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)

Relative Expression (log2-ratio):4.905531
Number of Samples:22 / 23
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)

Relative Expression (log2-ratio):4.8879333
Number of Samples:22 / 23
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; baseline; etarnecept; non-responder) / psoriasis study 25 (non-lesional; baseline; etarnecept; non-responder)

Relative Expression (log2-ratio):4.8474503
Number of Samples:14 / 13
Experimental psoriasis study 25 (lesional; baseline; etarnecept; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; etarnecept; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 5 (NCT00867100; lesional; baseline) / psoriasis study 5 (NCT00867100; non-lesional; baseline)

Relative Expression (log2-ratio):4.8260603
Number of Samples:24 / 24
Experimental psoriasis study 5 (NCT00867100; lesional; baseline)
Lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from lesional skin at baseline.
Control psoriasis study 5 (NCT00867100; non-lesional; baseline)
Non-lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from uninvolved, non-lesional skin at baseline.

psoriasis study 24 (lesional; baseline; etarnecept; responder) / psoriasis study 24 (non-lesional; baseline; etarnecept; responder)

Relative Expression (log2-ratio):4.7904396
Number of Samples:21 / 21
Experimental psoriasis study 24 (lesional; baseline; etarnecept; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; etarnecept; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.